Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 56, 5375-5379, December 1, 1996]
© 1996 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, L.
Right arrow Articles by Gerson, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, L.
Right arrow Articles by Gerson, S. L.

Mismatch Repair Mutations Override Alkyltransferase in Conferring Resistance to Temozolomide but not to 1,3-Bis(2-chloroethyl)nitrosourea1

Lili Liu, Sanford Markowitz and Stanton L. Gerson2

Division of Hematology and Oncology, Department of Medicine, and the University/Ireland Cancer Research Center, Case Western Reserve University School of Medicine, and University Hospital of Cleveland, Cleveland, Ohio 44106-4937

Cells with the mutator phenotype are tolerant to methylating damage from N-methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanine, exhibit replication repair errors, and have recently been found to be mutant in mismatch repair (MMR). However, resistance of cell lines with these defects to clinically used chemotherapeutic agents and the relationship of this resistance to expression of O6-alkylguanine-DNA alkyltransferase (AGT), which repairs DNA damage caused by methylating agents, has not been demonstrated. We compared resistance to the methylating agent temozolomide (TMZ) and to the chloroethylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), with and without AGT inhibition by O6-bG in several colorectal carcinoma cell lines. Two cell lines had known microsatellite instability (replication repair error-positive) and high levels of AGT, as well as a mutation in one of two MMR genes, hMLH1 (HCT116) or GTBP (HCT15). Cell line SW480 had wild-type MMR genes and high AGT, and HCT116+Ch3 has previously been transduced with chromosome 3 (carrying wild-type hMLH1) and thus has a "corrected" MMR phenotype. SW480 exhibited the expected sensitivity to TMZ and BCNU and marked potentiation of cytotoxicity by O6-bG. In contrast, HCT15 and HCT116 were markedly resistant to TMZ and were not sensitized by O6-bG-mediated inhibition of AGT, whereas the sensitivity pattern in HCT116+Ch3 cells was similar to that in SW480. All cell lines were sensitized to BCNU by O6-bG. Thus, tumor cells with defects in MMR appear particularly resistant to methylating agents in a manner that overrides dependence on AGT and its inhibition by O6-bG. However, these cells use AGT for resistance to chloroethylating agents, providing an alternative strategy for alkylating agent therapy.

1 Supported in part by the following grants from the Public Health Service: R01ES06288, UO1CA75525, R01CA63193 and P30CA43703.

2 To whom requests for reprints should be addressed, at Division of Hematology and Oncology, Case Western Reserve University School of Medicine, BRB-3, 10900 Euclid Avenue, Cleveland, OH 44106-4937.

Received 8/ 7/96. Accepted 10/17/96.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. F.Z. Batista, W. P. Roos, M. Christmann, C. F.M. Menck, and B. Kaina
Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks
Cancer Res., December 15, 2007; 67(24): 11886 - 11895.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al.
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
Clin. Cancer Res., November 15, 2007; 13(22): 6712 - 6718.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Horton, P. A. Thompson, S. L. Berg, P. C. Adamson, A. M. Ingle, M. E. Dolan, S. M. Delaney, M. Hedge, H. L. Weiss, M.-F. Wu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study
J. Clin. Oncol., November 1, 2007; 25(31): 4922 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al.
Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment
Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Yan, A. Bulgar, Y. Miao, V. Mahajan, J. R. Donze, S. L. Gerson, and L. Liu
Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase II{alpha}
Clin. Cancer Res., March 1, 2007; 13(5): 1532 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al.
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Rubie, J. Chisholm, A. S. Defachelles, B. Morland, C. Munzer, D. Valteau-Couanet, V. Mosseri, C. Bergeron, C. Weston, C. Coze, et al.
Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group New Agents Group Study
J. Clin. Oncol., November 20, 2006; 24(33): 5259 - 5264.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. K. Mirzoeva, T. Kawaguchi, and R. O. Pieper
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
Mol. Cancer Ther., November 1, 2006; 5(11): 2757 - 2766.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Ueno, S. H. Ko, E. Grubbs, Y. Yoshimoto, C. Augustine, Z. Abdel-Wahab, T.-Y. Cheng, O. I. Abdel-Wahab, S. K. Pruitt, H. S. Friedman, et al.
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Mol. Cancer Ther., March 1, 2006; 5(3): 732 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Liu and S. L. Gerson
Targeted Modulation of MGMT: Clinical Implications
Clin. Cancer Res., January 15, 2006; 12(2): 328 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M. Fontes, B. M. Davis, L. P. Encell, K. Lingas, D. T. Covas, M. A. Zago, L. A. Loeb, A. E. Pegg, and S. L. Gerson
Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells
Mol. Cancer Ther., January 1, 2006; 5(1): 121 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, S. Verstovsek, D. Thomas, S. Gerson, J. Cortes, S. Faderl, A. Ferrajoli, F. Ravandi, S. Kornblau, G. Garcia-Manero, et al.
Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Clin. Cancer Res., November 1, 2005; 11(21): 7817 - 7824.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. L. Cheng, S. P. Johnson, S. T. Keir, J. A. Quinn, F. Ali-Osman, C. Szabo, H. Li, A. L. Salzman, M. E. Dolan, P. Modrich, et al.
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
Mol. Cancer Ther., September 1, 2005; 4(9): 1364 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Hegi, A.-C. Diserens, T. Gorlia, M.-F. Hamou, N. de Tribolet, M. Weller, J. M. Kros, J. A. Hainfellner, W. Mason, L. Mariani, et al.
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
N. Engl. J. Med., March 10, 2005; 352(10): 997 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine
Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea
Clin. Cancer Res., February 15, 2005; 11(4): 1539 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Tentori, O. Forini, E. Fossile, A. Muzi, M. Vergati, I. Portarena, C. Amici, B. Gold, and G. Graziani
N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor-{kappa}B DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity
Mol. Pharmacol., February 1, 2005; 67(2): 572 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, S. Verstovsek, A. Ferrajoli, S. Jeha, M. Beran, C. Koller, et al.
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Clin. Cancer Res., May 1, 2004; 10(9): 2908 - 2917.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. Hammond, J. R. Eckardt, J. G. Kuhn, S. L. Gerson, T. Johnson, L. Smith, R. L. Drengler, E. Campbell, G. R. Weiss, D. D. Von Hoff, et al.
A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
Clin. Cancer Res., March 1, 2004; 10(5): 1645 - 1656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. J. Curtin, L.-Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan-Koch, S. E. Webber, B. W. Durkacz, H. A. Calvert, Z. Hostomsky, et al.
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells
Clin. Cancer Res., February 1, 2004; 10(3): 881 - 889.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Liu, Y. Nakatsuru, and S. L. Gerson
Base Excision Repair as a Therapeutic Target in Colon Cancer
Clin. Cancer Res., September 1, 2002; 8(9): 2985 - 2991.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Liu, S. Schwartz, B. M. Davis, and S. L. Gerson
Chemotherapy-induced O6-Benzylguanine-resistant Alkyltransferase Mutations in Mismatch-deficient Colon Cancer
Cancer Res., June 1, 2002; 62(11): 3070 - 3076.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. L. Gerson
Clinical Relevance of MGMT in the Treatment of Cancer
J. Clin. Oncol., May 1, 2002; 20(9): 2388 - 2399.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, I. Portarena, G. Zupi, E. Bonmassar, and G. Graziani
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
Blood, March 15, 2002; 99(6): 2241 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. Gururangan, I. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon II, J. M. Provenzale, R. E. McLendon, S. Tourt-Uhlig, et al.
Phase I study of GliadelTM wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
Neuro-oncol, October 1, 2001; 3(4): 246 - 250.
[Abstract] [PDF]

Home page
 Nucleic Acids ResHome page
C.-T. Lin, Y. L. Lyu, H. Xiao, W.-H. Lin, and J. Whang-Peng
Suppression of gene amplification and chromosomal DNA integration by the DNA mismatch repair system
Nucleic Acids Res., August 15, 2001; 29(16): 3304 - 3310.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Pepponi, G. Graziani, S. Falcinelli, P. Vernole, L. Levati, P. M. Lacal, E. Pagani, E. Bonmassar, J. Jiricny, and S. D'Atri
hMSH3 overexpression and cellular response to cytotoxic anticancer agents
Carcinogenesis, August 1, 2001; 22(8): 1131 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. P. Spiro, L. Liu, S. Majka, J. Haaga, J. K. V. Willson, and S. L. Gerson
Temozolomide: The Effect of Once- and Twice-a-Day Dosing on Tumor Tissue Levels of the DNA Repair Protein O6-Alkylguanine-DNA-Alkyltransferase
Clin. Cancer Res., August 1, 2001; 7(8): 2309 - 2317.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Meyers, M. W. Wagner, H.-S. Hwang, T. J. Kinsella, and D. A. Boothman
Role of the hMLH1 DNA Mismatch Repair Protein in Fluoropyrimidine-mediated Cell Death and Cell Cycle Responses
Cancer Res., July 1, 2001; 61(13): 5193 - 5201.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Markowitz
DNA Repair Defects Inactivate Tumor Suppressor Genes and Induce Hereditary and Sporadic Colon Cancers
J. Clin. Oncol., November 1, 2000; 18(90001): 75s - 80.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. E. Berry, T. W. Davis, J. E. Schupp, H.-S. Hwang, Niels de Wind, and T. J. Kinsella
Selective Radiosensitization of Drug-resistant MutS Homologue-2 (MSH2) Mismatch Repair-deficient Cells by Halogenated Thymidine (dThd) Analogues: Msh2 Mediates dThd Analogue DNA Levels and the Differential Cytotoxicity and Cell Cycle Effects of the dThd Analogues and 6-Thioguanine
Cancer Res., October 1, 2000; 60(20): 5773 - 5780.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M. Zeng, L. Narayanan, X. S. Xu, T. A. Prolla, R. M. Liskay, and P. M. Glazer
Ionizing Radiation-induced Apoptosis via Separate Pms2- and p53-dependent Pathways
Cancer Res., September 1, 2000; 60(17): 4889 - 4893.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. S. Friedman, T. Kerby, and H. Calvert
Temozolomide and Treatment of Malignant Glioma
Clin. Cancer Res., July 1, 2000; 6(7): 2585 - 2597.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
X. Qin, D. Shibata, and S. L. Gerson
Heterozygous DNA mismatch repair gene PMS2-knockout mice are susceptible to intestinal tumor induction with N-methyl-N-nitrosourea
Carcinogenesis, April 1, 2000; 21(4): 833 - 838.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Alvino, R. Pepponi, E. Pagani, P. M. Lacal, C. Nunziata, E. Bonmassar, and S. D'Atri
O6-Benzylguanine Enhances the In Vitro Immunotoxic Activity of Temozolomide on Natural or Antigen-Dependent Immunity
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1292 - 1300.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
L. Liu, P. Taverna, C. M. Whitacre, S. Chatterjee, and S. L. Gerson
Pharmacologic Disruption of Base Excision Repair Sensitizes Mismatch Repair-deficient and -proficient Colon Cancer Cells to Methylating Agents
Clin. Cancer Res., October 1, 1999; 5(10): 2908 - 2917.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. A. Johnson, M. L. Mierzwa, S. P. Fink, and L. J. Marnett
MutS Recognition of Exocyclic DNA Adducts That Are Endogenous Products of Lipid Oxidation
J. Biol. Chem., September 17, 1999; 274(38): 27112 - 27118.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. A. Hammond, J. R. Eckardt, S. D. Baker, S. G. Eckhardt, M. Dugan, K. Forral, P. Reidenberg, P. Statkevich, G. R. Weiss, D. A. Rinaldi, et al.
Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
J. Clin. Oncol., August 1, 1999; 17(8): 2604 - 2604.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
I M FRAYLING
Microsatellite instability
Gut, July 1, 1999; 45(1): 1 - 4.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. O'Driscoll, S. Martinelli, C. Ciotta, and P. Karran
Combined mismatch and nucleotide excision repair defects in a human cell line: mismatch repair processes methylation but not UV- or ionizing radiation-induced DNA damage
Carcinogenesis, May 1, 1999; 20(5): 799 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. E. Berry, C. Garces, H.-S. Hwang, K. Kunugi, M. Meyers, T. W. Davis, D. A. Boothman, and T. J. Kinsella
The Mismatch Repair Protein, hMLH1, Mediates 5-Substituted Halogenated Thymidine Analogue Cytotoxicity, DNA Incorporation, and Radiosensitization in Human Colon Cancer Cells
Cancer Res., April 1, 1999; 59(8): 1840 - 1845.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Anbazhagan, H. Fujii, and E. Gabrielson
Microsatellite Instability Is Uncommon in Breast Cancer
Clin. Cancer Res., April 1, 1999; 5(4): 839 - 844.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Reese, B. M. Davis, L. Liu, and S. L. Gerson
Simultaneous Protection of G156A Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Sensitization of Tumor Cells Using O6-Benzylguanine and Temozolomide
Clin. Cancer Res., January 1, 1999; 5(1): 163 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. D'Atri, L. Tentori, P. M. Lacal, G. Graziani, E. Pagani, E. Benincasa, G. Zambruno, E. Bonmassar, and J. Jiricny
Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis
Mol. Pharmacol., August 1, 1998; 54(2): 334 - 341.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Tentori, P. M. Lacal, E. Benincasa, D. Franco, I. Faraoni, E. Bonmassar, and G. Graziani
Role of Wild-Type p53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polymerase
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 884 - 893.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.